Anne Banos

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 799 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

Lotfi Benboubker, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · New England Journal of Medicine · 2014 · 786 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget et al. · Blood · 2016 · 326 citations · Full text

Medicine, Hematology, Oncology +9

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma

Thierry Façon, Meletios Α. Dimopoulos, Angela Dispenzieri et al. · Blood · 2017 · 271 citations · Full text

Medicine, Oncology, Hematologic Oncology +9

Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival

Hervé Avet‐Loiseau, Michel Attal, L. Campion et al. · Journal of Clinical Oncology · 2012 · 224 citations · Full text

Medicine, Hematology, Oncology +9